Earth Science Tech, Inc. (OTC: ETST) announced fiscal first-quarter 2027 results showing a 57% year-over-year increase in net income to $715,697, driven by revenue growth to $9.0 million, a 3% rise from the prior-year period. The company's gross profit climbed to $6.3 million, while operating cash flow more than doubled to $707,131. Total assets increased to $10.4 million, and diluted earnings per share improved to $0.003 from $0.001.
During the quarter, Earth Science Tech repurchased and retired more than 3.7 million common shares without incurring additional debt, signaling confidence in its financial trajectory. The company emphasized that all key operating subsidiaries remained profitable as it continues to expand the licensing footprint of its compounding pharmacy operations across the United States. Management is also evaluating opportunities to broaden its telehealth and pharmacy fulfillment platforms.
These results come as Earth Science Tech prepares for its annual shareholder meeting on Aug. 31, 2026, where investors will vote on proposals including the cancellation of the company's Series B Preferred Stock. Management will also provide updates on a potential exchange uplisting aimed at improving liquidity and market visibility. An uplisting could attract a broader base of institutional investors and enhance the company's credibility in the public markets, potentially reducing the cost of capital and facilitating future growth initiatives.
The company's diversified holding structure integrates compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment, supported by real estate and asset management activities and a consumer products business. This vertical integration is central to its value proposition, aiming to streamline patient care from consultation to fulfillment.
For business and technology leaders, the financial performance underscores the growing demand for integrated healthcare services that combine traditional pharmacy with digital health solutions. The 57% net income growth and strong cash flow generation indicate operational efficiency and scalability, which are critical in a sector facing margin pressures. The company's focus on expanding its pharmacy licensing footprint could position it to capture market share as telehealth adoption continues to rise.
Investors and industry observers will be watching the shareholder meeting outcomes, particularly the proposed cancellation of Series B Preferred Stock, which could simplify the capital structure and potentially enhance shareholder value. The potential uplisting to a national exchange is another key development, as it would likely increase trading liquidity and attract more analyst coverage, making the stock more accessible to a wider range of investors.
Earth Science Tech's results also highlight the importance of operational discipline, as the company managed to increase net income significantly despite modest revenue growth, reflecting improved margins and cost controls. The share repurchase program, executed without adding debt, further strengthens the balance sheet and signals management's commitment to returning value to shareholders.
As the healthcare industry continues to evolve with technology-driven solutions, Earth Science Tech's integrated model may serve as a blueprint for other companies looking to combine traditional services with digital platforms. The company's ability to maintain profitability across all subsidiaries while pursuing expansion suggests a resilient business model that could withstand industry fluctuations.
The full press release with detailed financial statements is available at https://ibn.fm/WHicW. For ongoing updates, investors can visit the company's newsroom at https://ibn.fm/ETST.
